

## Special Issue

# BNCT Drug Development and Preclinical Testing

### Message from the Guest Editors

The appearance of hospital-based epithermal neutron sources has made boron neutron capture therapy (BNCT) a dedicated focus of innovative developments in radiation oncology. This binary treatment modality not only needs neutrons but also a carrier transporting B-10 selectively into cancer cells. This has fueled the quest for new compounds for BNCT and resurgence of interest in preclinical testing of these next-generation compounds. This Special Issue of *Cells* is dedicated to collating results of recent preclinical research related to the development and testing of novel boron-containing therapeutic compounds and publishing a collection of intelligible and clear reviews of the most challenging aspects of drug development for BNCT. You are invited to submit your contributions in the form of original research articles, reviews, or shorter perspective articles.

---

### Guest Editors

#### Prof. Dr. Wolfgang Sauerwein

1. Radiation Oncology, University Hospital Essen, University Duisburg, Strahlenklinik, Hufeland Street 55, 45122 Essen, Germany
2. EBG MedAustron GmbH, Marie Curie-Straße 5, 2700 Wiener Neustadt, Austria
3. Neutron Therapy Research Center, Okayama University, Okayama 700-8530, Japan
4. German Society for Boron Neutron Capture Therapy, 45122 Essen, Germany

#### Prof. Dr. Lucie Sancey

Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309 UGA, Allée des Alpes-Site Santé, 38700 La Tronche, France

#### Dr. Sunil Krishnan

Mayo Clinic Florida, Jacksonville, FL 32224, USA

---

### Deadline for manuscript submissions

closed (15 April 2023)



## Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/122786](https://mdpi.com/si/122786)

*Cells*

Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).